Further studies may be required to establish the molecular mechanism behind this counterintuitive adverse event to better understand the uses and risks of TNF inhibitor therapies as it relates to RA and psoriasis. Most individual reports do not contain details on the progression of the AEs over time. This evidence concerns the gene TNF and rheumatoid arthritis.